속보 • May 13
Veradermics Advances Oral Hair Loss Program With Positive Results and $766.8 Million Funding Veradermics reported positive Phase 2/3 topline results for its oral hair-loss candidate VDPHL01 in Study 302, supporting its potential as the first FDA-approved oral treatment for pattern hair loss in almost 30 years.
The company completed enrollment in pivotal Phase 3 Study 304 in male pattern hair loss and continues to enroll patients in Phase 3 Study 306 in female pattern hair loss.
Veradermics raised about $766.8 million through its IPO and follow-on offerings, which the company expects to use to fund operations into 2030 and advance its clinical programs.
The combination of positive late-stage data and multiple ongoing Phase 3 programs places Veradermics at a key development point where regulatory and clinical decisions may become major value drivers.
For investors, the sizeable cash position reduces near-term financing risk, while outcomes for VDPHL01 and future regulatory interactions remain central uncertainties to watch. 공시 • Apr 28
Veradermics, Incorporated has filed a Follow-on Equity Offering. Veradermics, Incorporated has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,350,000 공시 • Feb 10
Veradermics, Incorporated Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss Veradermics, Incorporated announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this milestone marks the completion of enrollment across both Phase 3 clinical trials of VDPHL01 in males, encompassing more than 1,000 participants. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements regarding the timing of completion of and data from the Phase 3 clinical trials for VDPHL01 for thetreatment of male and female pattern hair loss; the release profile of VDPHL01 and whether the release profile will achieve its intended effect; whether Veradermics will successfully file a new drug application for VDPHL01; and the projected size of the market for pattern hair loss treatments. Veradermics' anticipation that its success will depend on the approval and successful commercialization of VDPHL01, which is its lead product candidate, and if Veradermics is unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any other current or future product candidates, or experience significant delays in doing so, its business will be materially harm; risks related to preclinical and clinical development and that results of earlier studies and trials may not be predictive of future preclinical studies or clinical trial results; the risk that Veradermics may encounter substantial delays in preclinical and clinical trials, or may not be able to conduct or complete preclinical or clinical trials on the expected timelines, if at all; the risk that the U.S. Food and Drug Administration does not conclude that VDPHL01 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for VDPHL01 under Section 505(b)(2") are not as Veradermics expects, the approval pathway for those product candidates takes longer or costs more than anticipated; the risk that adverse events or undesirable side effects are caused by Veradermics' product candidates; competition from other companies; risks related to developing Veradermics' sales, marketing and distribution capability; the risk that even if Veradermics obtains regulatory approval for VDPHL01 or any other product candidates, such products may fail to achieve market acceptance; the risk that the commercial opportunity for VDPHL01 or Any other current or future product candidates may be smaller than Veradermics expects; the cash-pay healthcare market for VDPHL01 may limit Veradermics' ability to increase sales or achieve profitability; risks relating to effectively maintaining, promoting and enhancing Veradermics' reputation and VDPHL01 brand recognition in a cost-effective manner; risks related to Veradermics' need to grow its organization; the ability of Veradermics to successfully execute its intellectual property strategy for VDPHL01 and risks related to Veradermic' need to grow its organization. the ability of Veradermic to successfully execute its intellectual property strategies for VDPHL01 and risk related to Veradermics's ability to obtain and maintain sufficient intellectual property protection for VDPHL01 and other current and any future product candidates and other proprietary technologies; risks related to ongoing regulatory obligations for any approved products; risks related to Verader mics' reliance on third parties for the manufacture of drug or biological substances for preclinical studies and clinical trials and expectations that Veradermics will continue to do so for commercialization of any product candidates that are approved for marketing; risks related to VeraderMics' reliance and expected continued reliance on third parties to conduct preclinical studies and clinical trials; global macro conditions; global macro and regulatory obligations for any approved products. 공시 • Feb 04
Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million. Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 15,077,647
Price\Range: $17
Transaction Features: Sponsor Backed Offering 
